Wilmington Savings Fund Society FSB Lowers Stock Holdings in Masimo Co. (NASDAQ:MASI)

Wilmington Savings Fund Society FSB reduced its position in Masimo Co. (NASDAQ:MASI) by 72.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,717 shares of the medical equipment provider’s stock after selling 35,347 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Masimo were worth $2,267,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC boosted its holdings in Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after purchasing an additional 1,970,883 shares during the period. Westfield Capital Management Co. LP increased its holdings in Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. Assenagon Asset Management S.A. raised its position in Masimo by 916.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider’s stock valued at $35,713,000 after purchasing an additional 194,788 shares in the last quarter. Clearline Capital LP purchased a new position in shares of Masimo in the 3rd quarter valued at about $21,337,000. Finally, ING Groep NV grew its position in shares of Masimo by 143.3% during the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock worth $32,119,000 after buying an additional 141,900 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MASI. BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Finally, Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.40.

Masimo Stock Performance

NASDAQ MASI opened at $176.16 on Monday. The company has a fifty day moving average of $171.63 and a two-hundred day moving average of $147.10. The company has a market capitalization of $9.43 billion, a PE ratio of 121.49 and a beta of 1.02. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $183.14. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.